Advertisements

Ranitidine Hydrochloride

Quick links to important sections

Ranitidine Hydrochloride

Selected form

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ranitidine Hydrochloride

Property Description
Active ingredient Ranitidine
Form Tablet, Capsule, Solution for Injection
Pharmacological class Histamine H₂-receptor Antagonist (H2RA)
General purpose Reduction of gastric acid secretion
Origin Synthetic compound

Ranitidine Hydrochloride is a synthetic small molecule compound used primarily to modulate the level of acid in the stomach. Its active component is the drug Ranitidine, which is classified as a Histamine H₂-receptor Antagonist (H2RA). Ranitidine is the official International Nonproprietary Name (INN) for this active ingredient, which distinguishes it from various commercial products. The compound's effectiveness in reducing stomach acidity is clinically recognized and supported by pharmacological studies. Ranitidine is included in the Model List of Essential Medicines. The inclusion on this list signifies that the compound is considered necessary for addressing the priority healthcare needs of a population.


Composition and Available Forms

The medication is available in several dosage forms, most commonly including tablets, capsules, and a solution for injection. A distinctive feature of this INN is its availability in an effervescent tablet form, which dissolves quickly in water for rapid consumption, contrasting with standard solid tablets. As a synthetic drug, Ranitidine Hydrochloride requires the inclusion of solid excipients when prepared for oral administration. The formulation designed for intravenous (IV) or intramuscular (IM) use is an aqueous solution, allowing the medication to be administered systemically, bypassing the gastrointestinal tract when necessary. The variety of forms ensures flexibility in how the active ingredient, Ranitidine, is delivered. H₂-receptor antagonists, including Ranitidine, produce a significant and measurable reduction in gastric acid output. This action effectively performs the core function of suppressing stomach acidity.


General Purpose of H₂-Receptor Antagonists

The primary general purpose of Ranitidine Hydrochloride is to provide relief from discomfort by achieving a controlled reduction in gastric acid secretion. This is accomplished because the compound acts as a competitive inhibitor that targets specific receptors in the stomach lining. By blocking these H₂ receptors, the drug limits the production of acid, thereby lowering the acidity level in the stomach and reducing the irritation that contributes to symptoms of acid-related issues. This action is typically leveraged in managing conditions characterized by excess acid, such as providing short-term relief for episodes of heartburn.

Regulatory References

  1. Ranitidine entry in the WHO Electronic Essential Medicines List (eEML)
Advertisements

What side effects are possible with Ranitidine Hydrochloride?

Possible Side Effects and Safety Information

The safety profile of Ranitidine Hydrochloride details the officially documented adverse effects and safety constraints, classified by frequency and affected body systems as established in governmental regulatory documents.

Documented Adverse Reactions

The occurrence of adverse reactions is categorized in official labeling:

  • Common Reactions: These include headache, constipation, diarrhea, and abdominal discomfort or pain.
  • Rare Reactions: Examples include dizziness, somnolence, rash, arthralgias (joint pain), and reversible mental confusion (primarily in severely ill or older adults).
  • Very Rare Reactions: These cover serious events such as severe changes in blood counts (e.g., agranulocytosis), hepatic failure, acute pancreatitis, and arrhythmias.

System-Organ Classes and Serious Concerns

Adverse effects are documented across various System-Organ Classes (SOCs), including the Blood and Lymphatic System, Nervous System, Hepatobiliary System, and Cardiac System. Serious adverse reactions listed in regulatory information include life-threatening events like anaphylactic shock and hepatic failure.

Safety Considerations and Restrictions

Safety notes are provided for specific patient groups:

  • Renal and Hepatic Impairment: Caution is required, as the drug is primarily eliminated by the kidneys and metabolized by the liver. Dosage adjustments are often noted.
  • Acute Porphyria: The medicine is formally contraindicated in individuals with a history of acute porphyria due to the risk of precipitating acute attacks.

Regulatory Status: All Ranitidine products were formally recommended for suspension or withdrawal from many international markets, including the U.S. and E.U., due to the confirmed presence of the impurity N-nitrosodimethylamine (NDMA), a probable human carcinogen.

Advertisements

Overdose and Emergency Response

Ranitidine Hydrochloride Overdose and when to seek help

The official regulatory assessment regarding the acute toxicity of Ranitidine Hydrochloride indicates that, due to its specific mechanism of action, no particular problems are expected following overdosage. This finding suggests a low-risk profile for acute adverse outcomes. However, immediate medical attention is mandated following any suspected overdose scenario, reflecting the importance of professional monitoring and intervention.


When to Seek Urgent Help

Official regulatory guidance requires the user to contact a Poison Control Center right away or seek medical help from a healthcare practitioner or emergency department, even if there are no symptoms of overdose. If severe clinical signs manifest, such as collapse, seizure, trouble breathing, or the person is unresponsive, the user must call emergency services immediately as these represent critical, life-threatening outcomes.


Documented Manifestations and Management

Manifestations documented under the H₂-receptor antagonist drug class may include central nervous system effects like mental confusion and hallucinations, which have been reported predominantly in severely ill and elderly patients. The officially described treatment approach is symptomatic and supportive therapy as deemed appropriate by the medical team. The regulatory documents do not list a specific pharmacological antidote. As a procedural intervention for managing the condition, the drug may also be removed from the plasma by haemodialysis.

Advertisements

Therapeutic Uses of Ranitidine Hydrochloride

What Ranitidine Hydrochloride Treats: Main Uses and Benefits

Ranitidine is commonly used to help manage symptoms and conditions presenting with systemic or localized discomfort, providing supportive relief that contributes to overall comfort. Easing symptoms occurs across conditions such as peptic ulcers (stomach and intestinal sores), Gastroesophageal Reflux Disease (GERD), and certain conditions where symptoms relate to heightened physiological activity like pathological hypersecretion.

Symptomatic Relief for Heartburn and Acid Indigestion

This medication is generally used to address the immediate and frequent symptoms that interfere with daily functioning, such as the painful burning of heartburn and acid regurgitation. It offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports the patient during episodes of heightened discomfort by easing the overall symptom load.

Healing and Management of Ulcers and Reflux Disease

This medicine is relevant for easing symptoms associated with conditions involving inflammatory or irritative processes, such as ulcers and severe GERD. It may assist with healing tissues affected by these conditions, which helps maintain a sense of stability when symptoms are more noticeable and may assist with maintaining functional stability by addressing recurrent or episodic manifestations.


Quick Fact: Relief for Heartburn and Indigestion Ranitidine is commonly used to help with groups of symptoms that may appear suddenly or fluctuate, providing symptomatic relief when discomfort related to inflammatory or irritative states creates noticeable functional strain.

Regulatory References

  1. NIH MedlinePlus overview on Ranitidine
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Ranitidine Hydrochloride?

The official eligibility profile for Ranitidine Hydrochloride is defined by regulatory agencies and specifies the populations that are permitted, restricted, or prohibited from using the medicine.


Absolute Non-Eligibility (Contraindications)

Ranitidine Hydrochloride is strictly contraindicated and must not be used by two groups:

  • Patients with a known hypersensitivity to ranitidine or any of the inactive ingredients in the formulation.
  • Individuals with a history of acute porphyria, as the drug may precipitate an attack of this metabolic disorder.

Restricted and Conditional Use

Certain populations can only use the medicine under medical guidance due to physiological considerations or risk of drug accumulation:

  • Patients with Renal Impairment: Use is restricted in patients with significantly reduced kidney function (e.g., Creatinine Clearance less than 50 mL/min), often requiring a lower dose under supervision.
  • Pregnancy and Lactation: Use in pregnant or breastfeeding women is generally conditional and only recommended if considered medically essential, as the drug is known to cross the placenta and pass into breast milk.

Age-Related Eligibility

  • Adults and Adolescents (16 years) are generally eligible for use.
  • Pediatric Use: Is typically restricted to specific conditions under prescription, with an established minimum age of 1 month for some forms.
  • Neonates (under one month of age) are generally classified as a population where safety and efficacy are not established.
Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Ranitidine Hydrochloride is defined by its pharmacokinetic effects, primarily the reduction of gastric pH and its clearance via renal transporters.

pH-Dependent Absorption and Exposure

Ranitidine co-administration may reduce the absorption (decreased exposure) of medicines that require an acidic environment for dissolution. This group includes specific antivirals (like Atazanavir), certain antineoplastics (like Dasatinib and Erlotinib), and some azole antifungals (like Ketoconazole). Conversely, the official profile confirms that Ranitidine does not inhibit the liver's microsomal enzyme system.

Clearance and Plasma Levels

Ranitidine can increase the plasma concentration of other agents, such as Procainamide and its metabolite N-acetylprocainamide, due to competition for renal tubular secretion. The agent Propantheline is documented to delay and increase Ranitidine's own peak blood levels. Ranitidine absorption is not significantly impaired by food.

Timing and Population-Specific Notes

A mandatory timing rule exists for certain combinations: when used with Atazanavir/Ritonavir, Ranitidine must be administered simultaneously with, and/or at least 10 hours after the dose of the antiviral combination. Specific patient populations, such as those with impaired renal function (CrCl < 50 mL/min), require adjustment due to reduced clearance. Co-administration with Atazanavir/Ritonavir is not recommended in treatment-experienced pregnant women.

Advertisements

Mechanism of Action

How Ranitidine Hydrochloride Works


Competitive Blockade of the Histamine H₂-Receptor

Ranitidine functions as a competitive antagonist that selectively targets the Histamine H₂-receptors located on the gastric parietal cells. By binding reversibly to these receptors, the drug directly limits the binding of endogenous histamine, which is a fundamental initial step in the signal cascade that regulates hydrogen ion secretion.


Interruption of Intracellular Signaling Cascades

The blockade interferes with the subsequent intracellular signaling cascade by limiting the activation of the enzyme adenylate cyclase. This interruption reduces the intracellular formation of the second messenger cyclic AMP (cAMP), which serves as the molecular trigger for the final acid-secreting pump.


Resulting Physiological Acid Reduction

By reducing this signaling, the mechanism limits the primary stimulus for the Hydrogen-Potassium ATPase (Proton Pump), leading to a reduction in the extrusion of hydrogen ions ( H^+) into the stomach lumen. This physiological change reduces the overall concentration of hydrogen ions ( H^+) in the stomach contents.

Advertisements

Dosage and Administration Information

Administration Routes and Standard Regimens

Ranitidine is administered via the oral route as tablets, capsules, or solution, and through parenteral routes including intravenous (IV) and intramuscular (IM) injection. The administration method is determined by the patient’s clinical needs, with parenteral forms typically reserved for acute situations or when oral intake is not feasible. The oral form's absorption is not significantly affected by food, allowing it to be taken independently of meal times, although certain regimens specify dosing at bedtime for optimal acid suppression.


Dosing Frequency and Duration

Treatment with ranitidine is structured into two main patterns: acute therapy and long-term maintenance. For the treatment of active ulcers, the standard adult regimen is typically 150 mg twice daily or 300 mg once daily at bedtime, with courses commonly lasting from four to eight weeks. Once healing is achieved, the dose is reduced to 150 mg once daily at bedtime for long-term maintenance to prevent recurrence.


Parenteral Use and Population Adjustments

For parenteral administration, the usual dose is 50 mg given every six to eight hours. When administered as an IV bolus, the dose must be diluted and injected slowly over a minimum of five minutes. A critical administration principle is the requirement for dose adjustment in adults with renal impairment (creatinine clearance less than 50 mL/min), where the standard oral dose is reduced to 150 mg every 24 hours. The drug's use in pediatric patients is established using a weight-based dosing schedule.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Ranitidine Hydrochloride

Evidence for Studies on Active Ulcer Healing (Duodenal and Gastric)

Research has explored Ranitidine Hydrochloride in studies focusing on the active phase of duodenal and gastric ulcers. These studies primarily used short-term Randomized Controlled Trials (RCTs) applied in research contexts examining outcomes related to physical discomfort. Researchers focused on the ulcers' endoscopic healing rates and patient-reported outcomes describing perceived discomfort. The populations studied were adult patients with confirmed ulcers.

Studies focusing on duodenal ulcers reported the specific rates of healing that were measured during the study period. Research for benign gastric ulcers examined similar outcomes, describing short-term healing rates and patterns of symptom change in the studied groups. However, the evidence base is characterized by its short-term focus, meaning the initial research provided limited insight into long-term outcomes after the acute treatment phase concluded.


Evidence for Managing Gastroesophageal Reflux Disease (GERD) and Hypersecretory Conditions

The research base for managing Gastroesophageal Reflux Disease (GERD) comprises numerous double-blind, placebo-controlled RCTs. These studies were used in research exploring short-term symptom changes in adult patients presenting with outcomes capturing phases of heightened symptom activity. Researchers monitored the rate of symptom control and the endoscopic healing of erosive damage in the esophagus. Findings from these trials reported the measures of symptom control that were observed, and recorded observations on healing over defined time intervals.

In contrast, research into rare conditions, such as pathological gastric hypersecretory disorders, was evaluated in studies using different designs, mainly Case Series and Observational Studies. These studies observed physiological strain, specifically the production of gastric acid. Data show patterns related to acid reduction and symptom management in these unique patient groups, but the evidence is limited and relies on non-randomized designs and modest sample sizes.


Evidence for Symptom Relief and Preventing Ulcer Recurrence

Studies exploring the use of Ranitidine Hydrochloride for transient heartburn and acid indigestion were typically short-term, acute placebo-controlled RCTs. These trials were relevant in assessing episodic symptom patterns, examining outcomes related to acute changes. Researchers examined the time to onset and duration of symptomatic relief. Research provides insight into short-term changes, but these findings do not offer data on chronic, long-term symptom management.

Regarding maintenance therapy, research was conducted using longitudinal RCTs applied in studies examining patient-reported experiences. These studies monitored the rate of ulcer recurrence over defined time intervals. Findings describe patterns observed in these studies regarding the durability of healing, but there is limited information for long-term outcomes extending beyond the one-year study window.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ranitidine Hydrochloride (FAQ)


Q: How quickly does Ranitidine start working after I take it?

A: Official information suggests that symptomatic relief for conditions like Gastroesophageal Reflux Disease (GERD) is often reported to begin within 24 hours after starting therapy. For short-term relief, such as preventing heartburn symptoms, the medicine is commonly taken 30 to 60 minutes before exposure to food or drinks that might cause the symptoms.


Q: How long does the effect of one dose of Ranitidine usually last?

A: Official dosing guidelines, which specify use once or twice daily, describe a pattern of acid reduction that is intended to last for 12 to 24 hours. The duration depends on the specific dose and the condition being managed.


Q: What is the typical duration for a course of Ranitidine treatment?

A: The length of treatment depends on the specific condition being addressed. For healing active ulcers, treatment periods described in official documentation often range from four to eight weeks. If the drug is used for long-term maintenance to prevent the recurrence of healed ulcers, therapy may be continued for a longer period.


Q: Is it necessary to take Ranitidine with food or on an empty stomach?

A: Official documents confirm the drug can be taken with or without food. The body's absorption of ranitidine is generally not significantly reduced by taking it with food or common antacids.


Q: Does Ranitidine interact with common pain relievers like ibuprofen or aspirin?

A: Official regulatory documentation indicates that ranitidine has been studied and used in the context of gastrointestinal problems caused by nonsteroidal anti-inflammatory drugs (NSAIDs). This class of pain relievers includes medicines like ibuprofen and aspirin.


Q: Can Ranitidine be taken with other antacids, like Tums or Gaviscon?

A: Official documents state that the body's absorption of ranitidine is generally not significantly affected by the simultaneous use of antacids.


Q: Does Ranitidine interact with blood thinners?

A: Studies have examined the use of ranitidine alongside certain oral anticoagulants, like warfarin. Research using specific tested doses found no significant effect on warfarin clearance or prothrombin time.


Q: Does Ranitidine interact with supplements like iron or magnesium?

A: As an acid-reducing medicine, ranitidine may alter the absorption of some other products that depend on stomach acidity for dissolution, but specific dietary supplements are not consistently listed in official interaction profiles.


Q: Does Ranitidine affect the results of certain medical tests?

A: Official reports on adverse reactions indicate that potential changes in blood test results may be observed. These reported changes include alterations to markers of liver function and changes in blood cell counts or creatinine levels.


Q: Why did Ranitidine used to be sold over-the-counter and now it's not?

A: Regulatory agencies in the U.S. and other countries requested a market withdrawal for all ranitidine products due to the confirmed presence of the impurity N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen, and levels were found to increase over time under normal storage conditions.


Q: What is the difference between Zantac and Ranitidine?

A: Ranitidine is the official generic name (the active ingredient) for the drug, which belongs to a class called H2-receptor antagonists. Zantac was one of the common brand or trade names under which the active ingredient ranitidine hydrochloride was previously marketed and sold.


Q: Is Ranitidine only used for stomach ulcers?

A: Official indications include conditions beyond duodenal and benign gastric ulcers, such as reflux esophagitis, Zollinger-Ellison syndrome, and other conditions where reducing gastric acid secretion is desired.


Q: Can Ranitidine be used for acid reflux/GERD?

A: Official documentation for ranitidine includes the treatment of Gastroesophageal Reflux Disease (GERD) and endoscopically diagnosed erosive esophagitis, which is damage to the food pipe caused by acid reflux.


Q: Is it common to feel dizzy when first taking Ranitidine?

A: Official documentation classifies dizziness as a rare adverse reaction associated with the drug. Other central nervous system effects, such as somnolence and vertigo, are also listed as rare.


Q: Does Ranitidine cause fatigue or sleepiness?

A: Sleepiness, or somnolence, is listed in official documents as a rare adverse reaction. Generally, regulatory information categorizes most reported side effects by their frequency of occurrence.


Q: Can Ranitidine affect my mood or cause anxiety?

A: Official adverse reaction reports include rare cases of temporary mental confusion, agitation, and depression. These effects have been reported predominantly in severely ill patients or older adults.


Q: Are there certain foods or drinks I should avoid while taking Ranitidine?

A: Studies examining the use of ranitidine with alcohol indicate that no interaction of clinical significance occurs when alcohol is consumed in moderate amounts. Outside of a general statement on food's non-effect on absorption, specific food avoidance is not mandated in official documentation.


Q: Are there different strengths or doses of Ranitidine commonly available?

A: Ranitidine was available in several different strengths for oral administration, including lower and higher dose forms of tablets and capsules. An injection solution was also available for administration through other routes.


Q: Can Ranitidine cause hair loss or skin issues?

A: Official adverse reaction reports include rare cases of skin rash and swelling. Uncommon reports of alopecia (unusual hair loss or thinning) have also been documented.


Q: What does the research say about the long-term safety of Ranitidine?

A: The initial research on ranitidine often had a short-term focus, providing limited long-term safety data beyond the acute treatment phase. The subsequent market withdrawal was driven by the potential for the impurity NDMA, a probable human carcinogen, to increase in the product over time.


Q: Can Ranitidine affect vitamin B12 absorption?

A: Official documentation indicates that the long-term use of medicines that significantly reduce stomach acid may prevent the normal absorption of Vitamin B12 from the diet. This effect has been studied in the context of potential deficiency.


Q: Can Ranitidine cause headaches?

A: Headache is listed in official documents as a common adverse reaction associated with the use of ranitidine.


Q: Are there any known interactions between Ranitidine and alcohol?

A: Studies have examined the co-ingestion of ranitidine and alcohol and indicated that no interaction of clinical significance occurs when alcohol is consumed in moderate amounts.


Q: Does Ranitidine have any effect on blood pressure?

A: While the adverse reaction profile includes rare reports of arrhythmias (irregular heartbeat), which are cardiovascular effects, a direct effect on blood pressure is not specifically listed in official documentation.


Q: Are there studies on Ranitidine use in patients with liver issues?

A: Caution is generally advised for patients with liver issues because the drug is metabolized by the liver. Official adverse reaction reports include occasional cases of liver inflammation and rare cases of liver failure.


Q: Is Ranitidine considered a high-risk medication?

A: The market withdrawal was initiated due to the confirmed presence of the impurity N-nitrosodimethylamine (NDMA), a probable human carcinogen, and its potential to increase over time. This significant safety finding led to the drug's formal cessation of sale.


Q: What happens if I miss a dose of Ranitidine?

A: Official consumer guidance advises that if a dose is missed, it should be taken as soon as it is remembered, unless it is too close to the time for the next scheduled dose. Two doses should not be taken at the same time to make up for a missed one.


Q: Is it normal to have vivid dreams while taking Ranitidine?

A: The official documentation does not specifically mention vivid dreams. However, the adverse reaction profile lists rare Central Nervous System effects, including insomnia (trouble sleeping) and hallucinations, which can sometimes be linked to sleep disturbances.

Advertisements

How should Ranitidine Hydrochloride be stored and disposed of?

Storage Conditions

Ranitidine Hydrochloride must be stored at Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F), with excursions allowed up to 30 C. The product must be protected from light and stored in a tight, light-resistant container. Exposure to excessive heat and humidity must be avoided. As with all medications, it must be kept out of reach of children.


Disposal Instructions

Due to regulatory concerns regarding the potential for the NDMA impurity to increase over time, especially with storage at higher temperatures, all ranitidine products were requested to be withdrawn from the market. Consumers are instructed to stop taking the medication and dispose of it properly in the household trash. The recommended method is to mix the product with an unappealing substance (such as dirt or used coffee grounds) and place the mixture in a sealed bag before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ranitidine Hydrochloride found in:

A-Z Index: